Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 13,062 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Pain, Postoperative
Interventions: PMI-150 (intranasal ketamine), Placebo; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Florence, Alabama • Sheffield, Alabama + 13 more

Conditions: Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Interventions: Cemiplimab, Radiation Therapy, Therapeutic Conventional Surgery; Biological · Radiation · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Depressive Disorder, Major
Interventions: LY2216684, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more

Conditions: Pancreatic Neoplasms
Interventions: imexon in combination with gemcitabine, imexon placebo + gemcitabine; Drug
Lead sponsor: AmpliMed Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 48
States / cities: Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 41 more

Conditions: Binge Eating Disorder
Interventions: dasotraline 4mg, dasotraline 6mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 50
States / cities: Phoenix, Arizona • Beverly Hills, California • Encino, California + 44 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: AZD4045, Daratumumab, Aldesleukin; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Duarte, California • Denver, Colorado • Tampa, Florida + 7 more

Conditions: HIV Infection
Interventions: Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 94
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more

Conditions: Type 2 Diabetes
Interventions: BT-001, Physician-guided Standard of Care for type 2 diabetes; Device · Other
Lead sponsor: Better Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 3 more

Conditions: HIV Infections
Interventions: Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB, RPV-LA Loading Dose, CAB-LA Loading Dose, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more

Conditions: Brain and Central Nervous System Tumors
Interventions: tamoxifen citrate, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 237
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more

Conditions: Pulmonary Embolism
Interventions: Anticoagulation with heparin, EkoSonicTM Endovascular System; Drug · Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Newark, Delaware + 22 more

Conditions: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Interventions: ALXN2220; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 35
States / cities: Irvine, California • La Jolla, California • Palo Alto, California + 29 more

Conditions: Crohn Disease
Interventions: GED-0301, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 34
States / cities: Los Angeles, California • Newport Beach, California • San Diego, California + 28 more

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: LEO Pharma; Industry
Eligibility: Up to 16 Years
Enrollment: 8,071 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 198
States / cities: Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 155 more

Conditions: Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
Interventions: Rina-S, IC; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 69
States / cities: Mobile, Alabama • Phoenix, Arizona • Irvine, California + 51 more

Conditions: Human Immunodeficiency Virus, HIV Seropositivity
Interventions: iTransition; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Seasonal Allergic Rhinitis
Interventions: azelastine hydrochloride and fluticasone propionate, Dymista vehicle; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions: Bendamustine Hydrochloride, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Lenalidomide, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography, Prednisone, Umbralisib, Vincristine Sulfate; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 429
States / cities: Anchorage, Alaska • Tucson, Arizona • Anaheim, California + 292 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Deflazacort; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 5 Years and older
U.S. locations: 42
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 36 more

Conditions: HIV Infections
Interventions: Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,570 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Inhaled treprostinil solution, Placebo solution; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 65
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Cancer
Interventions: App-based behavioral intervention, Attention control group; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 39 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia • Lexington, Kentucky

Conditions: Asthma
Interventions: albuterol sulfate inhalation aerosol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Up to 23 Months
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Hoover, Alabama • Fort Mohave, Arizona • Jonesboro, Arkansas + 24 more

Conditions: Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions: Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate; Combination Product
Lead sponsor: Emory University; Other
Eligibility: 12 Months and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

A Study in Adult Patients With Major Depressive Disorder

A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer

A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

iTransition Development

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

Promoting Quality of Life Among Young Adult Cancer Survivors

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma